Vasoactive Intestinal Peptide vs BPC-157

Vasoactive Intestinal Peptide wins for rapid and targeted immune modulation (especially in CIRS/long-COVID protocols), circadian signaling, pulmonary vasodilation, and addressing neuroinflammatory cascades. Its selective action on VPAC receptors makes it a unique tool for immune reset and symptom clusters poorly responsive to typical recovery peptides.

BPC-157 wins for accelerating functional repair of tendons, ligaments, GI lining, and soft tissue; unparalleled versatility for everything from chronic joint pain to post-surgical recovery to oral GI protocols. Safety signals remain favorable in community use at typical dosing, and administration routes are flexible. Easier sourcing and broader use-cases make it the front-line option for most physique and looksmaxxing scenarios.

Pick Vasoactive Intestinal Peptide if:

• The research target is post-inflammatory fatigue or symptom flares post-COVID, mold exposure, or other CIRS-type drivers
• There is a focus on restoring circadian rhythm or optimizing neuroendocrine signaling
• Pulmonary vasodilation or lowering PA pressures is a documented target (e.g., during heavy cycles)
• Standard recovery and healing peptides (e.g., BPC-157, TB-500) have not addressed immune-driven or multi-system symptoms
• Modulating T cell regulation and dampening NF-κB-related cytokines is the goal

Pick BPC-157 if:

• The research model involves accelerated healing of tendons, ligaments, or chronic soft tissue injuries
• Gut repair (oral or injectable protocols) is the primary endpoint, especially "superdrol gut" or NSAID-induced GI damage
• Protocols require on-cycle joint and connective tissue protection, or post-injury/post-surgical recovery
• A broad safety and minimal side-effect profile is a priority
• The protocol calls for a versatile peptide that can stack easily with TB-500, GH, or other healing agents.